Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Valneva ( (VALN) ).
Valneva SE announced positive Phase 3 data for its chikungunya vaccine, IXCHIQ®, in adolescents, demonstrating a sustained 98.3% sero-response rate one year after vaccination. The data supports the potential extension of the vaccine’s usage to adolescents in the U.S., Europe, and Canada and aims to secure its first approval for endemic populations in Brazil. The vaccine, which is already approved for adults in the U.S., Europe, and Canada, showed high tolerability and long-lasting antibody response in the trial conducted in Brazil. Valneva, in collaboration with Instituto Butantan and CEPI, amplifies its global outreach by securing partnerships to improve vaccine access in low- and middle-income countries, addressing a significant unmet medical need highlighted by growing chikungunya outbreaks worldwide.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is known for its highly specialized and targeted approach, focusing on developing first-, best-, or only-in-class vaccine solutions. Valneva markets proprietary travel vaccines, including the world’s first and only chikungunya vaccine, and is involved in advancing vaccine candidates against Lyme disease, Shigella, Zika virus, and other global public health threats.
YTD Price Performance: -7.42%
Average Trading Volume: 41,100
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $357.4M
For detailed information about VALN stock, go to TipRanks’ Stock Analysis page.
